Kostja Paschalidis

TATs represent an exciting and fast-evolving class of targeted therapies with the potential for high therapeutic impact due to the potent, short-range cytotoxicity of alpha particles. While clinical interest and investment in these agents are growing rapidly, bringing up-and-coming alpha emitters such as 211-At and 212-Pb from early discovery into broad clinical use remains challenging.

This workshop will provide an integrated analysis from scientific foundations through to real-world supply chain considerations, addressing the technical, logistical, and commercial hurdles that must be overcome to enable the future success of TATs.

• Explore the radiophysical properties of promising alpha emitters including astatine-211 and lead-212
• Assess current and emerging industrial-scale production approaches – from cyclotron networks for 211-At to thorium-228-based generator systems for 212-Pb
• Identify challenges in logistics due to short half-lives and regulatory/licensing constraints, and best practices for supply preparedness
• Review the evolving market dynamics for alpha emitters, investment trends, and competitive positioning in the context of a growing radioligand therapy space

–

Outcome – Whitepaper on Alpha Supply Chain Roadmap-collaborative draft outlining strategic recommendations for scalable production and reliable distribution of 211-At and 212-Pb, including infrastructure gaps and potential solutions.